Canaccord backs bullish outlook for Vascular Solutions

|About: Vascular Solutions, Inc. (VASC)|By:, SA News Editor

Canaccord is out reiterating a Buy recommendation on shares of Vascular Solutions (VASC) as analyst Jason Mills sees "double-digit revenue and EPS growth" going forward, thanks to "solid core business and continued strong execution."

In a colorful note, Mills calls the preliminary injunction against BSX's Guidezilla extension catheter an "early Christmas present" and says "potential new reprocessing service could add more 'steak & sizzle' to the VASC story within 12 months."

Price target hiked to $25 from $22.50.